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INTRAUTERINE INFECTION IS the most common cause for preterm birth (18) and is also associated with increased neonatal morbidity among preterm infants (12, 27) . The fluid in the fetal lungs is mixed with the amniotic fluid (34) ; therefore, microbial particles and toxins that are present in amniotic fluid can invade the pulmonary airways and the parenchyma of the fetal lung and can interfere with prenatal lung development or directly affect the developing lung (24) . The structural maturation of the air spaces and septa as well as the onset of fetal surfactant synthesis are critical maturational processes in the fetal and perinatal period and are regulated by hormones and growth factors (19, 20) . Neuregulin (NRG) is involved in the initiation of fetal surfactant production (11) and its signaling receptor ErbB4 is prominently expressed in the fetal lung (56) . ErbB receptors are known for their regulatory roles in lung development (11, 33) and injury (13, 32) . ErbB4 downregulation leads to reduced fetal surfactant synthesis (29, 57) and its deletion delays fetal lung development (28) . Our recent studies in adult mice suggest that ErbB4 deletion also interferes with postnatal lung function, because of a persistence of chronic inflammation and structural anomalies such as alveolar simplification (37) . This phenotype is similar to the one seen in animals exposed to cytokines (24) or in preterm infants developing bronchopulmonary dysplasia (BPD). We therefore developed a model of intrauterine infection in the ErbB4-deleted mice to test the hypothesis whether LPS exposure potentiates the delay in fetal lung development and further increases inflammation in ErbB4-deleted lungs.
MATERIALS AND METHODS

Animals.
We used transgenic ErbB4-deleted (HER4 heartϪ/Ϫ ) mice, which have been rescued from their lethal cardiac defects by expressing human ErbB4 (HER4) cDNA under the cardiac-specific ␣-myosin heavy chain promoter (16) (kindly provided by Dr. Carmen Birchmeier in agreement with Dr. Martin Gassmann) . Animals were housed in the animal facilities of Hannover Medical School under pathogenfree conditions and the protocols were approved by the appropriate governmental and institutional authorities (05/1004). In total 32 fetuses were used for stereological and 37 fetuses for molecular biological evaluation at embryonic day (E) 18 . In details, for the stereological analysis we used 7 ErbB4 heartϩ/Ϫ and 7 ErbB4 heartϪ/Ϫ fetuses in the Sham normal saline (NS) receiving control group from four different pregnancies, and 10 ErbB4 heartϩ/Ϫ and 8 ErbB4 lungs from seven different pregnancies in the LPS group were used. Experimental design. LPS (4 g, LPS from Escherichia coli 0127:B8, Sigma-Aldrich Chemie, Steinheim, Germany) or 0.9% NS was administered intra-amniotically on E17 of gestation. Patent Blue V (200 l) (Guerbet, Roissy, France) was added to visualize the localization of the injection. Only fetuses within a blue stained amniotic cavity were used for analysis 24 h after the injection. The solution was injected from caudal transabdominal into the amniotic cavity of the left and right uterus. To avoid injection into the fetus, we aspirated amniotic fluid before we injected the LPS or NS. Lungs were used for 1) morphometric analyses of lung parenchyma and qualitative analysis of elastic fibers, 2) CD11b immunohistochemistry to detect inflammatory cells, 3) ELISA to measure tumor necrosis factor (TNF)-␣, and 4) surfactant protein (Sftp) expression studies. Genotyping of the transgene and the cardiac-specific promoter was performed as previously described (37) .
Tissue processing. Pregnant mice were anesthetized with 150 l of a stock solution of 300 l ketamine (Ketamin Graeub, Albrecht, Aulendorf, Germany) and 200 l Rompun (xylazine hydrochloride injection solution, Bayer Vital, Leverkusen, Germany) or by etherization (ether; J. T. Baker Chemicals, Groß-Gerau, Germany). Fetuses were removed by caesarian section and kept in ice-cold PBS until dissection. After fetal exsanguination, the thorax was opened and the heart and lung was removed en bloc. The left lung was fixed by immersion in 4% paraformaldehyde and 0.1% glutaraldehyde for at least 2 h. After several rinsing steps the lungs were cryoprotected overnight in 30% sucrose, subsequently frozen in liquid nitrogen, and stored at Ϫ80°C until further used for stereological and immunohistochemical analyses. The right lung was divided into blocks, which were snap frozen in liquid nitrogen and stored at Ϫ80°C until used for protein and RNA isolation.
Stereological analysis. Stereological analyses were carried out on a Nikon Eclipse 80i microscope (Tokyo, Japan) by using the Stereo Investigator version 6 software (MicroBrightField, Williston, VT). Three serial 6-m-thick hematoxylin and eosin-stained sections were used. In this study one section each of the apical, central, and basal level of the left lung were evaluated by the point and intersection counting methods (50) . Briefly, we determined the volume densities (V V) 1) of the mesenchyme, serving as a degree of the immaturity of the lung, 2) of the air spaces reflecting the opening of air-containing sacculi, and 3) of the alveolar septa, reflecting the maturity of the lungs. Furthermore, we evaluated 4) the surface densities (S V) of the alveolar septa, by which we determined the size of the gas-exchange area.
Detection of inflammatory cells in lungs and placentas. Inflammatory cells such as polymorphonucleated cells and monocytes express the ␤ 2-integrin CD11b as surface marker. Lung and placenta sections were immunostained by using a monoclonal rat anti-mouse CD11b antibody (clone M1/70.15, isotype IgG2b; 1:100; MorphoSys AbD, Düsseldorf, Germany) followed by the avidin-biotin-peroxidase complex staining. A biotin-conjugated affinity purified antibody (goat anti-rat IgG, Chemicon International Europe, Hampshire, UK; 1:500) was used as secondary antibody. Immunostained inflammatory cells were counted in each of the three sections in 300 -400 test fields (size of the test frame: 100 ϫ 100 m) with a constant interval of 400 m between the test fields by using a stereo investigator system (MicroBrightField) and were expressed as cell number per square millimeter, as described previously (41) .
Measurement of TNF-␣. Tumor necrosis factor-␣ (TNF-␣) was measured in homogenized fetal lung tissue by ELISA in accordance with the manufacturer's instructions (Mouse TNF ELISA Set II, BD Biosciences, Heidelberg, Germany). Briefly, 96-well ELISA plates were coated with 100 l capture antibody (1:250) and the samples (100 l/well) or standards were applied. After incubation for 2 h, bound TNF-␣ was detected with a biotinylated antibody by the streptavidin-horseradish peroxidase detection method. The optical density of each sample was determined at 450 nm by use of an ELISA reader.
Staining of elastic fibers. To assess possible morphological differences of elastic fibers, orcein staining was used with 1% orcein solution (1 g orcein; Merck KGaA, Darmstadt, Germany) in 100 ml 70% isopropyl alcohol (J. T. Baker, Deventer, Netherlands) and 1 ml 25% HCl. Air-dried sections were incubated in orcein for 30 min. This was followed by several rinsing steps.
Sftp expression. Western blot analyses for Sftpa1, Sftpb, Sftpc, and Sftpd were performed in whole fetal lung homogenates as previously described (37) . Protein expression was quantified by densitometric evaluations normalized to ␤-actin and expressed as percent of heterozygote control lungs. Furthermore, the normalized data were listed as numerical values with standard error of the mean (Table 1) .
Sftp mRNA expression. Real-time PCR for the Sftp mRNA was carried out as previously described (37) . Briefly, actin was used as a housekeeping gene to normalize Sftp cDNA levels. The cycle threshold (Ct) is defined as the number of cycles required for the fluorescent signal to cross the threshold (i.e., it exceeds background level). Ct levels are inversely proportional to the amount of target nucleic acid in the sample. We used a semiquantitative method to estimate the relative expression level of the Sftp genes by calculating the differences in the threshold cycles of the Sftp and the reference actin genes [differences in the threshold cycles (DCt) Table 2 .
Statistics. Differences were tested for significance (P Ͻ 0.05) by the nonparametric Kruskal-Wallis one-way ANOVA on ranks test by using the Sigma Stat 2.0 software program (Jandel Scientific, Erkrath, Germany). For statistical analysis of protein and mRNA expression, a t-test for equal and unequal variances was conducted when indicated. A level of P Ͻ 0.05 was considered significant. Results were presented as means Ϯ SE, unless otherwise stated.
RESULTS
LPS led to an influx of inflammatory cells into the chorioamnion.
The fetal and the maternal portion of the placenta exhibited a modest increase in inflammatory cells after LPS treatment (Fig. 1, B and D) . The chorioamnion also appeared swollen in the LPS-treated placenta (Fig. 1, B and D) .
LPS potentiated the delay in morphological development in ErbB4-deleted lungs. LPS-treated lungs of heterozygote control fetuses showed a histological picture similar to the lungs of NS-treated HER4
heartϪ/Ϫ mice with a significantly higher proportion of mesenchyme, resulting in diminished gas exchange 
areas (Fig. 2) . LPS-treated HER4 heartϪ/Ϫ mice exhibited the most pronounced inhibition of morphogenesis (Fig. 2D) . No sacculi were fully developed, which is in contrast to the sacculi of the control animals. Stereological analyses confirmed these findings (Fig. 3) . NS-treated fetal heterozygote control lungs of E18 mice (controls) had progressed to the saccular state in a normal timely fashion ( Fig. 2A) . LPS administration resulted in a delay in morphological maturation, characterized by less developed sacculi and a higher proportion of mesenchyme (Fig. 2B) . Compared with heterozygote control fetuses, LPS application significantly increased the volume density (V V ) of the mesenchyme from 5.0 Ϯ 1.5% (N ϭ 7) to 20.1 Ϯ 4.3% (N ϭ 10, P ϭ 0.01) (Fig. 3A) . Furthermore, the V V of the air space decreased significantly from 45.08 Ϯ 2.1% (N ϭ 7) to 31.0 Ϯ 2.3% (N ϭ 10, P ϭ 0.006) ( (Fig. 3C ). This was also true for the septal thickness (10.6 Ϯ 0.9 m Ϫ1 (N ϭ 7) in LPS-treated lungs compared with control lungs 12.9 Ϯ 0.6 m Ϫ1 (N ϭ 10, P ϭ 0.62).
In NS-treated ErbB4-deleted HER4 heartϪ/Ϫ fetal mice, the morphological development of the lung was also delayed, showing less fully developed sacculi (Fig. 2C) . The V V of the mesenchyme was significantly higher in these animals compared with the heterozygote controls [13.4 Ϯ 1.8% (N ϭ 7) and 5.0 Ϯ 1.5% (N ϭ 7, P ϭ 0.004), respectively] (Fig. 3A) . Compared with NS-treated ErbB4-deleted lungs, LPS application led to a significant delay in morphological lung development as well as to a more prominent inflammation (Fig. 2, D and E). Again, stereological analyses confirmed these findings (Fig. 3) . A significant increase of V V of the mesenchyme from 13.4 Ϯ 1.8% (N ϭ 7) to 47.8 Ϯ 5.4% (N ϭ 10, P ϭ 0.0001) was found in the LPS-treated ErbB4-deleted lungs. The V V of the air space decreased significantly from 40.6 Ϯ 1.8% (N ϭ 7) to 22.6 Ϯ 2.4% (N ϭ 8, P ϭ 0.0001) ( (N ϭ 8, not significant), respectively, were similar to the ones in heterozygote fetal HER4 heartϩ/Ϫ mice. 
LPS potentiated the influx of inflammatory cells in ErbB4-deleted fetal lungs. Lungs of control heterozygote HER4
heartϩ/Ϫ fetuses showed no signs of inflammation ( 
LPS induced TNF-␣ expression in ErbB4
-deleted fetal lungs. LPS administration did not change TNF-␣ expression in control animals (93 Ϯ 7%, N ϭ 10, P ϭ 0.6) but led to a significant increase of its expression in ErbB4-deleted lungs to 132 Ϯ 10% (N ϭ 8, P ϭ 0.05) compared with nontreated heterozygote and ErbB4-deleted control lungs (100 Ϯ 13%, N ϭ 3 and 100 Ϯ 14%, N ϭ 4, respectively) (Fig. 4G) .
LPS led to a further reduction and disorganization of elastic fibers in ErbB4-deleted fetal lungs. The well-organized long thick elastic fibers of normally developed vessel walls (Fig. 5A) , septae, and the fibers at the entrance of alveoli seen in heterozygote control animals appeared disorganized and mainly in clusters in lungs of ErbB4-deleted fetuses (Fig. 5B) . LPS treatment led to an overall decrease in elastic fibers in the lung parenchyma of control lungs (Fig. 5C ) and an even more pronounced disorganization of elastic fibers in ErbB4-deleted fetal lungs (Fig. 5D) .
LPS potentiated the ErbB4 deletion-induced increase in Sftp expression. LPS treatment significantly stimulated Sftpb (234 Ϯ 31%, N ϭ 14, P ϭ 0.008) and Sftpc (210 Ϯ 23%, N ϭ 13, P ϭ 0.002) expression in heterozygote control lungs. The expression of Sftpa1 (95 Ϯ 11%, N ϭ 11, P ϭ 0.8) and Sftpd (65 Ϯ 5%, N ϭ 11, P ϭ 0.0005) was decreased. The stimulatory effect was potentiated by the combination of LPS treatment and ErbB4 deletion, leading to an increase in Sftpa1 (203 Ϯ 24%, N ϭ 5, P ϭ 0.0009), an even more pronounced increase in Sftpb (373 Ϯ 50%, N ϭ 8, P ϭ 0.004), and Sftpc (329 Ϯ 37%, N ϭ 8, P ϭ 0.002) protein expression. Sftpd expression did not change significantly (84 Ϯ 5%, N ϭ 8, P ϭ 0.2). LPS treatment significantly increased the Sftpa1 (108 Ϯ 11%, N ϭ 11, P ϭ 0.0003), Sftpb (139 Ϯ 31%, N ϭ 14, P ϭ 0.02), Sftpc (119 Ϯ 23%, N ϭ 13, P ϭ 0.009), and Sftpd (19 Ϯ 5%, N ϭ 11, P ϭ 0.02) expression in ErbB4-deleted lungs compared with heterozygote control lungs treated with LPS (Fig. 6A) . Data given as normalized numerical values with standard error of the mean are listed in Table 1 .
LPS minimized the ErbB4 deletion-induced effects on Sftp mRNA expression. In contrast to the effect on Sftp expression, LPS treatment resulted in an upregulation of the mRNA expression of the collectins Sftpa1 (0.6 Ϯ 0.2 ϪDDCt, N ϭ 13, P ϭ 0.2) and Sftpd (0.7 Ϯ 0.3 ϪDDCt, N ϭ 13, P ϭ 0.3) and a significant downregulation of Sftpb (Ϫ2.7 Ϯ 0.4 ϪDDCt, N ϭ 10, P ϭ 0.003) and Sftpc (Ϫ3.1 Ϯ 0.2 ϪDDCt, N ϭ 17, P Ͻ 0.0001) in heterozygote control animals. The combination of LPS treatment and ErbB4 deletion resulted in a downregulation of the mRNA expression of all four Sftps (Sftpa1:Ϫ1 Ϯ 0.5 ϪDDCt, N ϭ 11, P ϭ 0.2; Sftpb: Ϫ1.1 Ϯ 0.6 ϪDDCt, N ϭ 10, P ϭ 0.1; Sftpc: Ϫ1.3 Ϯ 0.5 ϪDDCt, N ϭ 11, P ϭ 0.2; Sftpd: Ϫ0.7 Ϯ 0.6 ϪDDCt, N ϭ 10, P ϭ 0.5). However, LPS treatment significantly decreased the mRNA expression of Sftpa1 (Ϫ1.6 Ϯ 0.5 ϪDDCt, N ϭ 11, P ϭ 0.004) and Sftpd (Ϫ1.4 Ϯ 0.6 ϪDDCt, N ϭ 10, P ϭ 0.04) and significantly increased expression of Sftpb (1.4 Ϯ 0.5 ϪDDCt, N ϭ 10, P ϭ 0.04) and Sftpc (1.8 Ϯ 0.5 ϪDDCt, N ϭ 11, P ϭ 0.0007) in ErbB4-deleted lungs compared with heterozygote control lungs treated with LPS (Fig. 6B) . Data given as normalized numerical values with standard error of the mean are listed in Table 2 . 
DISCUSSION
Intrauterine LPS exposure models have been used to study the effect of intrauterine infection on fetal (4, 35) and postnatal lung development (43) . Here, we present for the first time a potential regulatory mechanism involved in the signaling of inflammatory injury in the developing lung. Intrauterine LPS exposure is known to cause a delay in the structural development of the lung (43), which is similarly seen in ErbB4-deleted fetal lungs (28) . To study the combined effects of both injuries and to elucidate interactions of both pathways we established a prenatal intra-amniotic infection model using ErbB4 transgenic mice (16) . LPS was injected transperitoneally into the amniotic cavity at E17. To avoid postoperative stress and maternal wound infections, which could falsify the outcome, the peritoneal cavity was not opened. The LPS solution was mixed with a dye to monitor the correct distribution within the amnion cavity. Only animals with blue dye in their amniotic sac were used for the evaluation. We analyzed the combined effects of LPS administration and ErbB4 deletion at E18, 24 h after intra-amniotic injection, since this time frame represents the transition from the canalicular (E16.5-17.5) to the saccular stage. We had previously shown that in ErbB4-deleted lungs the structural and functional development is mainly delayed at E17 with some compensatory catch up development seen at E18 (28) . The 24-h time frame between LPS injection and tissue harvest was also chosen because LPS has a short half-life (45) , as indicated by cytokine increases in the amniotic fluid and placenta within a few hours after the inflammatory stimulus (5, 17) . This increase is known to return to baseline levels after 24 h (17).
Our present results here show that the ErbB4-induced delay in structural lung development was further potentiated by LPS treatment, implying an important role for ErbB4 in the structural remodeling of LPS-induced lung injury. LPS effects on lung structure are in agreement with the clinical picture of infants born prematurely in the setting of prenatal infection and developing BPD, resulting in a defective development of the parenchyma in the distal lung (42) . Since more than 2.4 billion US dollars are spent annually on the care of infants with BPD, ranking second after asthma (38) , further knowledge of signaling pathways involved in inflammatory lung injury is needed to elucidate new avenues for therapeutic options in the prevention or treatment of BPD in the setting of preterm birth.
The growth factor NRG and its signaling receptors ErbB2, ErbB3, and ErbB4 play important roles in the developing fetal lung. NRG is involved in the initiation of fetal surfactant synthesis (11) and its signaling receptor ErbB4 is the most prominent ErbB dimer partner expressed in the fetal lung type II cells (29) . ErbB4 is essential for fetal surfactant synthesis (57) and regulates the progression of lung development over time (28) . Glucocorticoids, which are used in the clinical setting to promote maturation of the fetal surfactant system in impending preterm delivery, interfere with the organized ErbB receptor dimerization in the type II cells, leading to a switch from ErbB1/ErbB4 to ErbB2/ErbB4 dimer expression (10). Since glucocorticoids are also known for their inhibitory effects on structural lung development (19) , more insight into ErbB receptor regulation in normal lung development and lung injury would bring us closer to the goal of new treatment options for preventing or treating pathological aspects of BPD such as delay in alveolar development.
Our present results suggest that the combination of LPS exposure and pulmonary ErbB4 deletion had additive inhibitory effects not only on fetal lung morphogenesis, but also on the intensity of inflammation. Indeed, we found a significant pulmonary influx of macrophages and neutrophils 24 h after LPS treatment in both groups compared with NS-treated control animals. However, both inflammatory cell types and TNF-␣ expression were significantly increased in the ErbB4-deleted lungs, underlining the inflammatory response to LPS. TNF-␣ is most likely secreted by activated macrophages, other inflammatory cells, and epithelial cells (47) . We here only studied TNF-␣ expression and not other cytokines of the inflammatory cascade such as IL-1␤, IL-6, and IL-8 (17), because TNF-␣ is known to be the one major mediator in maternal infection and preterm delivery (54) and is an earlyresponse element in inflammation (44, 55) . There was no change in TNF-␣ expression 24 h after LPS treatment in HER4 heartϩ/Ϫ control lungs. This might be due to a significantly lower number of inflammatory cells in these lungs. Our results are in accordance with published data indicating a short half-life of this early-response cytokine to bacterial infections (45) . Increased Sftpa1 levels found in the heterozygote fetal lungs after LPS exposure can be involved in a potential inhibition of the LPS-induced TNF-␣ secretion (2). Another reason for this blunted response in fetal control lungs might be the known blended LPS recognition mechanisms in the developing airways (14, 30) . On the contrary, the presence of the chronic inflammation in fetal HER4
heartϪ/Ϫ lungs (28, 37) might have been the reason for a more pronounced response to LPS in these lungs. This overall underlines the importance of ErbB4 in inflammatory responses in the lung. However, the role of ErbB4 receptor during inflammation is not yet well understood. ErbB4 expression and signaling may be key elements in TNF-␣ responses in the developing lung, similar to what have been described in cultured intestinal epithelial cells in intestinal bowel disease (15) or in bronchial epithelial cells (15, 25) exposed to TNF-␣. ErbB4 is normally expressed at low levels in unchallenged epithelial tissues, and an upregulation by cytokines may represent a potential cytoprotective mechanism under inflammatory injury conditions. Alveolar epithelial cells express TLR4. TLR4, which is the signaling receptor for LPS (22) , appears to be required for the LPSinduced changes in type II cell number during lung development (35) . The interaction of TLR4 with LPS may potentially disrupt epithelial-mesenchymal interactions and inhibit distal airway branching and alveolarization (35) . The role of TLR4 in structural lung development was further documented in transgene C.C3H-Tlr4
Lps-d mice lacking functional TLR4 (36) . Compared with wild-type animals, the LPS effects were much less pronounced in this transgenic strain, suggesting that the TLR4/NF-B pathway is required for the LPS effect in lung injury (36) . Furthermore, TLR4 activation leads to an inhibition of fibroblast growth factor-10 (FGF-10) expression (6) . FGF-10 is required for saccular lung development and its inhibition results in an abnormal saccular airway morphogenesis (6, 48) . Since the ErbB4-deleted fetal lungs exhibit an inhibition of morphological development exactly at this stage in lung development, a contribution of this receptor in the transition from canalicular into the saccular state is postulated (28). It might be speculated that there are interactions between ErbB receptor signaling and LPS-induced TLR4/FGF10 signaling. Further research is needed to elucidate the exact role of ErbB4 in the lung inflammation specifically during lung development.
The observed decrease and disorganization of elastic fibers in the parenchyma of LPS-treated fetal lungs may indicate additional interactions between LPS, lung cells, and hematopoietic cells. LPS may induce not only the expression of proinflammatory cytokines such as TNF-␣, but also the activation of elastin-degrading enzymes such as cathepsin in neutrophils (49), leading to an enhanced influx of granulocytes. The decrease and disorganization of elastic fibers seem to be more pronounced in ErbB4-deleted lungs, suggesting a regulatory role of ErbB4 receptor in the regulation and function of elastic fibers. The greatly reduced or fragmented elastin may be one reason for an insufficient alveolarization process, seen in the ErbB4-deleted lungs (28, 37) . Deposition of intact elastin at the crest of the primary septa is necessary for controlled budding of secondary septa and therefore essential in the process of alveolarization (7, 8) . Antenatal LPS application is known to interfere with this process in the lamb (52) and the rat model (43) . The significant role of elastin in terminal airway branching in the canalicular and saccular phase of lung development has been demonstrated in the elastin knockout mice. The lungs of these animals have fewer dilated air sacs with attenuated tissue septa in the saccular stage of development (51) . Another growth factor, important for alveolarization and involved in inflammatory lung injury, is transforming growth factor (TGF)-␤ 1 , a known key regulator in lung development. Overexpression of TGF-␤ 1 during intrauterine infection may potentiate the decrease in alveolarization in the developing lung (26) .
The higher degree of inflammation after LPS application in ErbB4-deleted lungs underlines the important role of ErbB4 in inflammatory lung injury and might partly be explained by the significant downregulation of the collectins Sftpa1 and Sftpd, two members of the Sftp family that are important for innate immunity (53) . The levels of these two proteins were not significantly changed 24 h after LPS exposure. Despite the fact that a discrepancy between protein level and mRNA level is well known, in particular for secreted proteins (1, 21) , our finding a difference in expression level might be due to the half-life of the proteins. Sftpa1 and Sftpd mRNA were upregulated in LPS-treated heterozygote control fetuses as described by others in adults (31) and preterm mice (39) . Both Sftps act as opsonins and are capable of aggregating LPS (9, 46). Sftpa1 and Sftpd are able to interact directly with cell surface pattern recognition receptors such as CD14 or TLRs (40) , modulating the LPS response and reducing the inflammation (9). Since both Sftp mRNAs were downregulated in LPS-treated ErbB4-deleted fetal lungs, it might be speculated that the loss of ErbB4 leads to a decreased LPS aggregation by collectins, leading to a higher influx of inflammation cells in the lung tissue.
The effect of LPS on Sftpb and Sftpc levels is similar to the upregulation of both Sftps seen in chronic exposure to intraamniotic endotoxin (3) . This agrees with the clinical observation that infants born in the presence of chorioamnionitis present with less surfactant deficiency at birth. However, a downregulation of Sftpb in acute lung injury after LPS exposure has been described (23) . We found a downregulation of the mRNA of both proteins after short-term exposure to LPS in this study. ErbB4 deletion in the lung clearly interfered with the effect of LPS on these two Sftps, leading to a more pronounced increase in the protein and less dramatic fall in the mRNA. This suggests that rescue mechanisms might be in place in the case of ErbB4 deletion, which take over function specifically during injury as seen here in this LPS model. Further detailed elucidation of the involved signaling is necessary.
In summary, the overall effects of the combination of inflammation and ErbB4 deletion point toward a differential involvement of ErbB4 in inflammation-induced lung injury, specifically in the progression of structural and functional lung development. It might be speculated that ErbB4 is involved in the prevention of structural delay of inflammatory injury in the developing lung but helps promote inflammatory-induced effects on Sftpb and Sftpc. Further analyses of the exact regulatory role of ErbB4 in the developing lung are needed to advance treatment options for fetal inflammatory lung injury, interfering with the organized progression of fetal lung development.
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